Results 41 to 50 of about 52,424 (257)
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline
Antibiotics, 2021 Novel antimicrobial agents, approved for clinical use in past years, represent potential treatment options for various infections. In this review, we summarize the most important medical and microbiological features of three recently approved ...
Béla Kocsis +2 more
doaj +1 more source
Early Endpoints for Acute Bacterial Skin and Skin Structure Infections [PDF]
Antimicrobial Agents and Chemotherapy, 2012 In this issue of the journal, [Friedland et al.][1] ([4][2]) present a retrospective analysis of the two CANVAS trials ([3][3]), employing the newer endpoints from the U.S. Food and Drug Administration (FDA) ([7][4]).
openaire +2 more sources
, 2022 Dalbavancin is a second-generation lipoglycopeptide approved since 2014 to treat acute bacterial skin and skin-structure infections (ABSSSI). Dalbavancin is characterized by Gram-positive activity and novel pharmacokinetic properties allowing prolonged ...
Righi, Elda +4 more
core +1 more source
Pathogens, 2022 Atopic dermatitis (AD) is a condition with a complex and unclear aetiology. Possible causes of AD encompass alterations in the structure and function of the epidermal barrier, disturbances in the skin microbiome, immune factors, allergens, bacterial and ...
Danuta Nowicka +2 more
doaj +1 more source
Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection
Western Journal of Emergency Medicine, 2020 Introduction: A small percentage of patients with skin infections later develop necrotizing fasciitis (NF). Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department (ED)
Urania Rappo +5 more
doaj +1 more source
Dalbavancin in the treatment of skin and soft tissue infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2018 Dalbavancin is a semi-synthetic lipoglycopeptide registered for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive microorganisms, including MRSA.
Nikulin A.A., Khachatryan N.N.
doaj +1 more source
Vancomycin Combined With Clindamycin for the Treatment of Acute Bacterial Skin and Skin-Structure Infections [PDF]
Clinical Infectious Diseases, 2015 Acute bacterial skin and skin-structure infections (ABSSSIs) are common causes of hospital admissions. These infections are often caused by methicillin-resistant Staphylococcus aureus; therefore, vancomycin remains a commonly used therapy. The purpose of this study was to compare hospital length of stay (LOS) in patients treated with vancomycin ...
Kurt A, Wargo +2 more
openaire +2 more sources
World Journal of Emergency Surgery, 2017 Background Surgical site infections (SSIs) constitute a major clinical problem in terms of morbidity, mortality, duration of hospital stay, and overall costs. The bacterial pathogens implicated most frequently are Streptococcus pyogenes (S. pyogenes) and
G. Sganga +3 more
doaj +1 more source
Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections [PDF]
, 2016 In 2013 the US Food and Drug Administration (FDA) issued recommendations and guidance on developing drugs for treatment of skin infection using a new definition of acute bacterial skin and skin-structure infection (ABSSSI).
Concia, E +31 more
core +1 more source
, 2018 Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern.
Urania Rappo +5 more
core +1 more source